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Abstract  Lung  nodules  are  commonly  found  on  computed  tomography  (CT)  and  need  a  stan-
dardized approach  in  order  to  avoid  misdiagnosing  lung  cancer  and  delaying  surgical  excision
whilst simultaneously  avoiding  unnecessary  invasive  procedures  if  the  lesions  prove  to  be
benign. Great  advances  have  been  made  in  the  last  decade  in  various  areas  affecting  the
management  of  lung  nodules:  the  understanding  of  the  molecular  mechanisms  behind  car-
cinogenesis,  a  new  classiﬁcation  of  lung  adenocarcinoma,  new  data  on  lung  cancer  screening,
widespread  use  of  multi-detector  row  CT  and  development  of  volumetric  analysis  software  for
nodules. Recent  decision-making  algorithms  are  based  on  the  size,  density  and  follow-up  of  the
nodule. The  distinction  between  solid  nodules,  sub-solid  nodules  and  pure  ground  glass  nodules
is fundamental,  and  has  a  strong  correlation  with  the  histologic  spectrum  of  adenocarcinoma.
In the  absence  of  criteria  suggesting  benign  disease,  the  radiologist’s  report  should  offer  one  of
the following  two  options:  follow-up  based  on  the  recommendations  if  the  nodule  is  equivocal,
or multidisciplinary  discussion  to  consider  invasive  management  if  the  nodule  is  highly  suspi-
cious of  malignancy.  Recent  data  from  this  statement  are  reviewed  and  practical  guidelines  are
offered based  on  international  expert  consensus  opinion.
© 2013  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.Lung  nodules  are  very  commonly  found  on  computer  tomography  (CT)  which  leads  the
doctor  to  question  whether  or  not  they  are  malignant.  In  his/her  investigation  report,  the
radiologist  must  rank  the  diagnostic  possibilities  and  offer  appropriate  management  based
on  the  morphology  of  the  nodule  and  its  clinical  context.  This  management  may  range
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tissue,  and  are  not  speciﬁc  for  lung  adenocarcinoma  as  they082  
rom  no  treatment,  without  follow-up,  to  surgical  resection.
t  should  always  optimize  the  beneﬁt-risk  balance,  i.e.  not
eave  a  potentially  malignant  nodule  to  progress,  whilst
t  the  same  time  limiting  invasive  investigations,  patient
nxiety  and  the  radiation  delivered  by  repeated  CT  scans.
he  selected  strategy  should  follow  recommendations  incor-
orating  recent  ﬁndings  from  an  extensive  and  rapidly
hanging  literature.  The  imaging  features  of  the  nodule,  and
herefore  the  role  of  the  radiologist,  are  essential  for  the
eﬁnition  of  this  management.
In 2002,  a  review  of  the  management  strategy  recom-
endations  for  lung  nodules  was  published  in  the  Journal
e  Radiologie  [1].  This  strategy  needs  to  be  updated  after
 decade  which  has  seen  many  advances  in  lung  can-
er  understanding  and  imaging.  The  Journal  de  Radiologie
iagnostique  et  Interventionnelle  is  therefore  offering  its
eaders  a  new  state  of  the  art  review.  The  ﬁrst  part  of  this
rticle  is  a  review  of  the  different  advances  which  impact
n  the  management  of  a  lung  nodule.  It  then  describes  the
iagnostic  approach,  based  on  recommendations  published
y  expert  consensus  groups.  It  then  offers  the  reader  a  sum-
ary  table  as  a  practical  decision-support  tool.
eﬁnitions
 lung  nodule  is  deﬁned  as  a  focal  opacity  whose  largest
iameter  is  between  3  mm  and  3  cm  in  length  [2].  The  term
icronodule  is  reserved  for  opacities  under  3  mm  in  diam-
ter  and  the  term  mass  is  used  for  opacities  over  3  cm
iameter.  The  accuracy  of  diameter  measurement  is  fun-
amental  as  the  size  of  a  nodule  correlates  closely  with  its
ikelihood  of  malignancy.  The  percentage  malignancy  rate  in
he  ELCAP  screening  study  was  1%  for  nodules  under  5  mm  in
ize,  24%  for  those  between  6  and  10  mm,  33%  between  11
nd  20  mm  and  80%  for  nodules  over  20  mm  in  size  [3]. Diam-
ters  are  measured  in  the  parenchymal  window  on  native
ransverse  axial  CT  slices,  which  may  be  a  source  of  errors
f  the  nodule  is  asymmetrical  and  not  spherical.  If  the  nod-
le  is  small,  then  measurements  must  be  taken  after  the
mage  has  been  magniﬁed.  As  a  result  of  inaccuracies  in  man-
al  measurements  of  diameter,  semi-automated  volumetric
easurement  techniques  have  been  developed  [4].
igure 1. Examples of solid (a), sub-solid (b) and pure ground glass (c
a
a
wM.  Lederlin  et  al.
Alongside  these  geometrical  measurements,  densitomet-
ic  analysis  of  the  lung  nodule  has  also  become  essential  and
as  been  made  possible  by  row  CT  technology  which  allows
ontinuous  millimeter  sections  to  be  acquired.  The  terms
olid  nodule,  sub-solid  nodule  and  ground  glass  nodule  were
ntroduced  by  Claudia  Henschke  in  2002  [5]. A  solid  nod-
le  has  a  homogeneous  tissue  density  which  obscures  the
ascular  structures  passing  through  it.  A  pure  ground  glass
odule  has  a  lower  density  which  does  not  obscure  vascular
nd  bronchial  structures  and  a  sub-solid  or  mixed  nodule  has
oth  components,  often  in  the  form  of  a  central  solid  nod-
le  surrounded  by  a  peripheral  ground  glass  halo  (Fig.  1).
his  densitometric  distinction  is  justiﬁed  by  their  different
ehaviors  in  terms  of  malignancy.  The  malignancy  rate  for
ub-solid  nodules  was  63%  in  the  ELCAP  study  compared  to
8%  for  pure  ground  glass  nodules  and  7%  for  solid  nodules
5].  The  lowest  proportion  of  malignant  nodules  is  therefore
he  solid  ones,  although,  paradoxically,  a  lung  cancer  more
ften  presents  as  a  solid  nodule  than  as  a  ground  glass  nod-
le  [6,7]. Indeed,  the  vast  majority  of  nodules  in  screening
tudies  were  solid  but  small  and  therefore  benign.  Note  that
he  densitometric  analysis  of  a  nodule  cannot  be  separated
rom  its  geometric  analysis.
dvances in the understanding of
olecular mechanisms in bronchial cancer
hese  advances  mostly  concern  adenocarcinoma,  the  com-
onest  but  also  most  varied  form  of  lung  cancer,  from  a
adiological,  clinical,  histological  and  molecular  perspec-
ive.  Adenocarcinomas  diagnosed  late  (stages  IIIB  and  IV)
ake  up  almost  80%  of  cases;  the  management  of  these  has
hanged  signiﬁcantly  in  recent  years.  Several  genes  involved
n  oncogenesis  (‘‘oncogenic  drivers’’)  have  been  identiﬁed
t  the  same  time  as  biomarkers  and  targeted  treatments
ave  been  developed.
These  oncogenes  may  cause  deregulations  or  point  muta-
ions  which  are  acquired  and  only  present  in  malignant) nodules.
re  also  found  in  colorectal  and  breast  cancer,  melanoma
nd  blood  malignancies,  to  give  a  few  examples.  The  most
idely  studied  mutations  in  lung  oncology  are  those  for  the
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that  the  overly  vague  term  ‘‘mixed  type  adenocarcinoma’’
no  longer  be  used  as  the  vast  majority  of  invasive  adeno-
carcinomas  are  made  up  of  several  histological  subtypes.
Each  adenocarcinoma  should  now  be  classiﬁed  according  to
Boxed  text  1  IASLC/ATS/ERS* classiﬁcation  of
bronchial  adenocarcinomas.
Pre-invasive  lesions:
• atypical  adenomatous  hyperplasia;
• adenocarcinoma  in  situ  (formerly:  or
bronchioloalveolar  carcinoma);
• minimally  invasive  adenocarcinoma.
Invasive  adenocarcinomas:
• lepidic  predominant  adenocarcinoma  (formerly:
non-mucinous  bronchioloalveolar  carcinoma);
• acinar  predominant  adenocarcinoma;
• papillary  predominant  adenocarcinoma;
• micropapillary  predominant  adenocarcinoma;
• solid  predominant  adenocarcinoma.
Invasive  variants:
• invasive  mucinous  adenocarcinoma  (formerly:
mucinous  bronchioloalveolar  carcinoma);
• colloid  adenocarcinoma;
• well-differentiated  fetal  adenocarcinoma;
• enteric  adenocarcinoma.
*Management  strategy  of  pulmonary  nodule  in  2013  
gene  coding  for  epidermal  growth  factor  receptor  (EGFR)
which  is  a  tyrosine  kinase  transmembrane  protein.  These
mutations  are  responsible  for  overexpression  of  the  EGFR
protein  which  accelerates  tumor  cell  proliferation.  They
are  generally  unrelated  to  smoking  and  are  more  com-
mon  in  women.  They  are  found  in  approximately  10  to  15%
of  Caucasian  patients  and  in  more  than  30%  of  patients
of  Asian  origin  [8—10].  Most  people  with  these  mutations
respond  to  the  tyrosine  kinase  inhibitors  (TKI),  which  block
overexpression  of  the  EGFR  protein.  The  ﬁrst  commercially
available  molecule  was  Geﬁtinib  (Iressa®),  which  was  shortly
followed  by  Erlotinib  (Tarceva®).  Response  rates  in  patients
with  the  mutation  are  over  60%,  with  a  median  survival  of
approximately  2  years,  whereas  patients  without  the  muta-
tion  have  a  response  rate  of  between  0  and  5%  and  a  median
survival  of  only  one  year  [11].  The  EGFR-TKIs  are  now  indi-
cated  for  ﬁrst-line  treatment  of  patients  with  inoperable
adenocarcinoma  with  the  mutation  [12],  and  according  to
the  Institut  National  du  Cancer  (INCa)  recommendations
[13],  patients  with  advanced  adenocarcinoma  should  be
tested  routinely  for  the  EGFR  gene  mutation.
Mutations  other  than  those  involving  EGFR,  which  are
often  mutually  exclusive,  have  also  been  found:
• the  EML4-ALK  rearrangement  which  is  found  in  5  to  7%  of
adenocarcinomas,  often  the  mucinous  form,  which  makes
them  sensitive  to  Crizotinib  (Xalkori®)  [14—18];
• the  KRAS  gene  mutation,  which  is  more  common  in  smok-
ers,  and  which  may  reﬂect  resistance  to  erlotinib  and
geﬁtinib  [19,20];
• other  more  recently  discovered  mutations  (BRAF,  HER2,
PIK3CA,  AKT1,  MEK1,  CMET,  ROS1)  are  currently  routinely
tested  for  [21,22];
• some  oncogenic  drivers  have  also  been  found  in  squamous
cell  carcinoma,  the  second  leading  cause  of  lung  cancer,
although  the  incidence  of  this  is  falling  [23].
The  development  of  these  biomarkers  and  targeted  treat-
ments  has  therefore  started  a  new  ‘‘theranostic’’  era  in
the  palliative  care  of  non-small  cell  lung  cancer.  INCa  has
made  this  one  of  its  priorities  by  starting  a  huge  devel-
opment  program  of  molecular  biology  tests  in  28  hospitals
throughout  France  [13].  Only  a  minority  of  patients  currently
receive  these  new  treatments  and  a  substantial  proportion
of  those  patients  ﬁnally  become  resistant  to  TKIs.  However,
new  discoveries  are  made  every  week  and  many  new  areas
of  treatment  are  opening  up  [24].  Molecular  phenotyping  is
also  promising  in  reﬁning  tumor  characteristics,  as  in  the
case  of  multiple  nodules  where  it  should  be  possible  to  dis-
tinguish  between  the  metastases  from  the  same  clone  and
several  synchronous  primary  lesions  [25].
New histological classiﬁcation of lung
adenocarcinomas
Lung  adenocarcinomas  currently  make  up  between  40  and
50%  of  primary  lung  cancers.  This  is  a  group  of  heterogeneous
tumors  with  many  subtypes,  which  have  extremely  different
prognoses.  The  classiﬁcation  of  adenocarcinomas  was  com-
pletely  revised  in  2011  to  simplify  and  adapt  it  to  advances
in  molecular  biology  [26].  The  authors  emphasize  the  mul-
tidisciplinary  nature  of  this  new  classiﬁcation,  which  must1083
ow  create  a  common  language  for  the  different  medical
pecialists  who  manage  lung  adenocarcinomas.
Pre-invasive  lesions,  which  have  a  post-resection  5-year
urvival  rate  of  almost  100%,  have  been  redeﬁned  taking
ccount  of  their  size  and  level  of  cellular  atypia  (Boxed
ext  1).  The  new  classiﬁcation  abolishes  the  use  of  the  term
‘bronchioloalveolar  carcinoma’’  which  was  considered  to
e  too  inaccurate  and  could  be  used  to  describe  several
ntities  which  have  since  been  clearly  deﬁned  as  follows:
atypical  adenomatous  hyperplasia:  a  proliferation  of  atyp-
ical  pneumocytes  along  the  alveolar  walls,  not  exceeding
5  mm  in  diameter.  This  is  considered  to  be  a  precursor  of
lung  adenocarcinoma;
adenocarcinoma  in  situ:  a  lesion  under  3  cm  in  diame-
ter,  consisting  exclusively  of  the  lepidic  subtype  which  is
deﬁned  by  a  preserved  alveolar  architecture.  This  has  a
5-year  survival  of  100%  [27,28];
minimally  invasive  adenocarcinoma:  a  lesion  under  3  cm
in  diameter,  consisting  predominantly  of  the  lepidic  sub-
type,  with  an  invasive  component  less  than  5  mm  in  size
with  no  necrosis  or  pleural,  vascular  or  lymphatic  inva-
sion.  This  has  a  very  good  prognosis  after  resection,  with
a  5-year  survival  of  nearly  100%  [29,30];
invasive  adenocarcinoma  with  a  predominant  lepidic  com-
ponent:  a  lesion  with  an  invasive  component  measuring
more  than  5  mm  in  diameter;
invasive  mucinous  adenocarcinoma:  the  new  name  for
multicentric  bronchioloalveolar  carcinoma.
For  surgically  excised  invasive  lesions,  it  is  recommendedIASLC:  International  Association  for  the  Study  of
Lung  Cancer;  ATS:  American  Thoracic  Society;  ERS:
European  Respiratory  Society.
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he  predominant  architectural  subtype  or  component  (lep-
dic,  acinar,  papillary,  micropapillary  or  solid)  (Boxed  text
,  Fig.  2).  The  predominantly  lepidic  adenocarcinomas  are
ess  invasive  and  carry  a  better  prognosis  than  the  other  sub-
ypes.  Predominantly  acinar  or  papillary  adenocarcinomas
re  intermediate  grade,  whereas  the  predominantly  solid  or
icropapillary  adenocarcinomas  are  high  grade  and  carry
he  poorest  prognosis.  This  histological  classiﬁcation  has  a
igniﬁcant  prognostic  impact,  which  is  independent  of  TNM
tage  [31].
The  lepidic  subtype  is  deﬁned  by  a  proliferation  of  atyp-
cal  cells  (type  II  pneumocytes  and  Clara  cells)  along  the
lveolar  walls,  without  invasion  and  therefore  without  alve-
lar  collapse.  Because  of  the  persistent  air  spaces  within  the
lveoli,  this  tissue  has  a  relatively  low  CT  density  and  there
s  a  good  correlation  between  the  ground  glass  appearance
ithin  the  tumor  and  the  lepidic  component  [28,32].  Tissue
r  solid  components  on  CT  represent  the  invasive  histologi-
al  component  [33].  The  natural  progression  of  pre-invasive
esions  is  slow,  although  the  invasive  component  increases
radually  in  parallel  with  decreasing  prognosis  [34—37].
here  is  probably,  therefore,  a  continuum  between  atypical
denomatous  hyperplasia,  adenocarcinoma  in  situ,  mini-
ally  invasive  adenocarcinoma  and  invasive  disease  [38].
herefore,  densitometric  analysis  of  a  nodule  allows  us  to
pproach  the  diagnosis  of  these  lesions  (Fig.  3).  Several
T
t
igure 2. Histological appearance of ﬁve components of invasive ade
d), and solid (e).
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igure 3. Spectrum of lung adenocarcinomas with radio-pathological M.  Lederlin  et  al.
tudies  have  shown  that  the  proportion  of  ground  glass  area
ithin  the  tumor  is  a  good  prognostic  indicator,  indepen-
ently  of  the  dimensions  of  the  adenocarcinoma  [39—41].
The  authors  of  the  new  classiﬁcation  propose  that  only
he  size  of  the  invasive  component  should  be  used  in  deter-
ining  T  status,  either  from  CT  (c-TNM)  or  histological
p-TNM)  ﬁndings.  Several  studies  have  suggested  that  the
ize  of  the  invasive  solid  portion  is  a  better  prognostic  indi-
ator  than  the  total  size  of  the  lesion  [42—45]. Results  of
ngoing  clinical  studies,  however,  are  needed  before  this
roposal  can  be  validated  and  possibly  incorporated  into  the
ighth  version  of  the  TNM  classiﬁcation.  The  new  classiﬁca-
ion  also  provides  recommendations  for  performing  biopsies
nd  cytology  samples.  In  particular,  they  recommend  that
urely  ground  glass  nodules  should  not  be  biopsied.  On  the
ther  hand,  for  invasive  lesions  a  sufﬁciently  large  amount
f  tissue  should  be  obtained,  particularly  if  they  appear  to
e  inoperable  on  CT,  in  order  to  allow  histological  exami-
ation,  immunohistochemistry  and  molecular  typing  to  be
arried  out.he  issue  of  lung  nodules  is  becoming  increasingly  linked
o  the  question  of  screening.  Lung  cancer  has  a  number
nocarcinomas: lepidic (a), acinar (b), papillary (c), micropapillary
ground
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of  features  making  it  suitable  for  mass  screening:  its  high
disease-speciﬁc  mortality,  a  deﬁned  at-risk  population,  its
high  prevalence  in  this  population,  the  long  clinical  latent
period,  the  fact  that  most  of  the  diseases  are  inoperable
when  the  diagnosis  is  made  from  symptoms,  and  the  fact
that  early  disease  treated  surgically  carries  a  good  progno-
sis,  with  a  10-year  survival  of  almost  90%  [46].  Screening
for  lung  cancer  with  an  annual  chest  radiograph  has  not
been  shown  to  be  beneﬁcial  [47],  nor  has  the  use  of  serum
markers,  cytological  sputum  analysis  or  expired  air.  Since
the  1990s,  chest  CT  has  been  thought  to  be  very  promis-
ing  for  screening  examinations  as  it  has  a ten-fold  greater
detection  power  than  standard  radiography  for  uncalciﬁed
nodules  [48—50].  Published  observational  studies  over  the
last  decade  [3,51—55]  have  shown  that  CT  screening  in  an
at-risk  population  diagnoses  between  0.4  and  2.7%  of  people
with  cancers,  mostly  stage  I.  The  effectiveness  of  screening,
however,  can  only  be  demonstrated  by  showing  a  reduction
in  cancer-speciﬁc  mortality  which  implies  prospective  ran-
domized  inclusion  of  a  large  number  of  patients.  We  had  to
wait,  therefore,  until  2011  and  the  results  of  the  National
Lung  Screening  Trial  (NLST)  for  proof  that  CT  scan  screening
was  effective  [56].  This  study  was  conducted  in  33  North
American  centers  and  included  more  than  53,000  smokers
(55—74  years  old,  >  30  pack-years)  or  former  smokers  who
quit  smoking  within  the  previous  15  years.  The  subjects  were
randomized  into  two  arms:  annual  CT  scan  for  3  years  com-
pared  to  annual  chest  radiograph  for  3  years.  After  a  median
follow-up  period  of  6.5  years,  lung  cancer  mortality  was
reduced  to  20.3%  in  patients  in  the  CT  arm.  An  observational
Japanese  study  reported  similar  results  [57], although  two
other  randomized  studies  have  failed  to  conﬁrm  the  results
of  the  NLST  [58,59].  These  studies,  however,  did  not  have
the  statistical  power  of  the  NLST  as  they  included  a  smaller
number  of  patients  (3000  to  4000  compared  to  53,000  in  the
NLST).
Either  way,  the  position  on  screening  is  not  deﬁnitive
and  several  questions  remain,  such  as  the  cost-effectiveness
ratio,  the  radiation  delivered  by  repeated  CT  scans,  the
large  number  of  false  positives  on  CT  scans  (98%  in  the
NLST  study),  and  the  risk  of  over-diagnosis.  One  study  pub-
lished  in  2009  estimated  that  25%  of  lung  cancers  identiﬁed
by  screening  would  not  in  fact  have  been  fatal  because
of  the  frequent  smouldering  nature  of  the  disease  and
the  comorbidities  present  in  smokers  [60].  In  addition,  the
methodology  of  the  NLST,  which  was  an  exclusively  North
American  study,  cannot  necessarily  be  extrapolated  to  other
healthcare  systems.  Scans  were  all  read  in  expert  centers,
which  is  not  necessarily  possible  in  practice  and  could  pro-
duce  different  results.  Each  country,  therefore,  needs  to
establish  its  own  need  for  lung  screening  and  the  screening
methods.
Joint  work  in  France  between  the  Intergroupe  Franco-
phone  de  Cancérologie  Thoracique  (IFCT:  the  Francophone
Thoracic  Cancerology  Intergroup),  the  Groupe  d’Oncologie
thoracique  de  Langue  Franc¸aise  (GOLF:  the  French  Thoracic
Oncology  Group)  and  the  Société  d’Imagerie  Thoracique
(SIT:  the  Thoracic  Imaging  Society)  has  provided  an  answer
to  clinicians  faced  with  a  request  for  screening.  The  main
points  are  summarized  below,  although  we  suggest  readers
refer  to  the  original  publication  which  appeared  recently  in
Annals  of  Oncology  [61].  Currently,  screening  only  occurs  on
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he  basis  of  an  individual  patient  making  an  active  request.
n  view  of  the  signiﬁcant  results  of  the  NLST  study,  the
uthors  felt  that  it  should  not  be  possible  to  refuse  screening
o  a  patient  that  has  requested  it  and  that  it  is  reasonable
o  offer  screening  to  at-risk  patients.  It  should  be  noted  that
ther  European  countries,  such  as  Italy,  feel  that  there  are
till  too  many  uncertainties  to  extrapolate  the  results  of  the
LST  to  current  clinical  practice.  The  French  expert  group
mphasizes  the  need  for  verbal  and  written  patient  infor-
ation  on  the  beneﬁts  and  risks  of  lung  cancer  screening.
n  particular,  people  must  be  informed  about  the  risk  of
alse  positive  results  and  for  any  subsequent  investigations.
he  rate  of  needless  invasive  procedures  in  the  NLST  study
surgery,  bronchoscopy  or  needle-biopsy)  was  2.6%,  approx-
mately  10%  of  which  caused  complications  (0.24%  of  the
hole  screened  population).  The  risks  of  radiation  must  also
e  explained.  The  same  inclusion  criteria  are  used  as  for  the
LST  study:
age  between  55  and  74  years  old;
smokers  of  more  than  30  pack-years,  either  current  or  who
have  stopped  within  the  last  15  years;
no  active  cancer,  respiratory  or  hepatic  impairment,  or
unexplained  weight  loss  in  the  last  12  months;
no  lung  infection  over  the  last  12  weeks.
Within  current  knowledge,  screening  should  be  annual
nd  continued  for  at  least  3  years.  A  study  published  in  2011
howed  that  stopping  screening  was  associated  with  a  sig-
iﬁcant  increase  in  cancer  deaths  [62].  According  to  the
rench  recommendations,  screening  does  not  require  dual
eading  or  a  computer-aided  detection  (CAD)  automated
odule  detection  system  [61,63]. A  recent  publication  from
he  NELSON  group,  however,  suggests  that  CAD  might  be
sed,  adjusting  the  sensitivity  to  reduce  the  number  of
alse  positives  [64].  Signs  of  COPD  should  be  mentioned
n  the  ﬁnal  report  [65]. Finally,  it  is  important  that  the
nnual  screening  consultations  are  accompanied  by  strong
nd  repeated  encouragement  to  stop  smoking.
ung nodule volumetry
t  is  generally  accepted  that  a solid  nodule  which  remains
table  in  size  for  2  years  is  benign  [66—68]. The  follow-up
lgorithms  therefore  recommend  2-year  follow-up  for  equiv-
cal  solid  nodules  [1,69].  Tumor  growth  can  be  assessed  from
epeated  CT  during  this  period.  Longitudinal  comparisons  of
he  diameter  of  small  nodules,  however,  are  imprecise  [4,70]
nd  a  5-mm  nodule  which  has  doubled  in  volume  would  only
n  fact  have  increased  by  1.3  mm  in  diameter.  This  ﬁgure  is
elow  the  intra-observer  variability,  which  is  between  1.3
nd  1.7  mm.  For  this  reason,  only  changes  in  diameter  of  at
east  2  mm  are  deemed  to  be  signiﬁcant  for  manual  mea-
urements.  Semi-automated  volume  measurement  is  more
eliable,  although  at  present  it  is  not  incorporated  into  the
ECIST  criteria,  nor  into  the  TNM  stage,  nor  into  the  Fleis-
hner  Society  recommendations.
A  three-dimensional  volume  approach  has  been  shown  to
e  more  precise  and  reproducible  than  single  diameter  mea-
urement  [71,72]  and  volumes  measured  at  two  different
imes  can  be  used  to  estimate  tumor  growth  [73]  by  cal-
ulating  the  volume  doubling  time  (VDT)  by  the  equation:
1V
n
a
c
a
b
t
u
v
v
c
d
s
f
s
h
g
n
i
n
f
c
i
i
r
o
8
8
o
a
l
t
d
a
n
t
m
c
m
i
i
t
k
t
i
r
p
i
b
i
W
U
m
t
a
s
a
i
s
I
r
i
f
n
u
1
e
w
i
[
b
s
o
a
a
s
[
a
s
[
s
i
e
m
a
a
5
i
m
M
B
w
r
s
a
c
m
m
•
•
s
s
m
C086  
DT  =  (t.ln2)/ln  (Vf/Vi)  where  Vi  =  the  initial  volume  of  the
odule,  Vf  =  ﬁnal  volume,  t  =  time  between  the  two  CT  scans
nd  ln  =  Napier  logarithm.  The  software  packages  which  are
urrently  available  automatically  measure  the  volume  of
 nodule  at  two  different  times  and  incorporate  the  time
etween  the  two  CT  scans  to  calculate  a  volume  doubling
ime.  Volume  measurements  have  been  validated  for  nod-
les  between  5  and  10  mm  in  diameter,  which  represent  a
olume  of  approximately  50  to  500  mm3 [74].  Changes  in
olume  of  at  least  25%  are  deemed  to  be  signiﬁcant.  The
urrent  cut-off  for  malignant  versus  benign  nodules  is  a
oubling  time  of  400  days,  usually  calculated  from  two  CT
cans  performed  3  months  apart  [74,75].  This  method  there-
ore  avoids  the  conventional  2-year  follow-up,  at  least  in
traightforward  situations.  An  earlier  check  at  one  and  a
alf  months  has  even  been  proposed  [76].  Some  people  sug-
est  reducing  the  cut-off  of  400  days  in  order  to  reduce  the
umber  of  false  positives,  although  the  risk  in  this  situation
s  that  adenocarcinomas  with  a  lepidic  predominant  compo-
ent,  which  grow  more  slowly,  would  be  missed.  Takashima
ound  that  the  volume  doubling  time  of  a  squamous  cell
arcinoma  is  122  days,  whereas  the  doubling  time  of  an
nvasive  adenocarcinoma,  adenocarcinoma  in  situ  and  atyp-
cal  adenomatous  hyperplasia,  were  384,  567  and  988  days
espectively  [77].  Hasegawa  reported  mean  doubling  times
f  149  days  for  solid  nodules,  457  days  for  mixed  nodules  and
13  days  for  ground  glass  nodules  in  a  3-year  follow-up  of
2  malignant  nodules  [78].  The  concept  of  remaining  stable
ver  2  years  (doubling  time  >  730  days)  therefore  does  not
pply  to  pure  or  partial  ground  glass  nodules  which  require
onger  follow-up.  In  addition,  volumetry  is  not  considered
o  be  sufﬁciently  reliable  for  ground  glass  nodules  [74,79],
espite  some  encouraging  results  [80].  A  novel,  promising
pproach  for  mixed  nodules  would  involve  measuring  the
odule  mass,  by  taking  account  of  volume  and  density  of
he  two  components  [81].
Volumetry  software  packages  are  based  on  different
athematical  algorithms  (density  threshold,  shape  analysis,
ombined  mode).  The  variability  between  volume  measure-
ents  using  these  algorithms  may  be  as  high  as  25%  [82]  and
t  is  therefore  important  to  use  the  same  software  for  the
nitial  and  repeat  scans.  The  two  scans  also  need  to  have
he  same  acquisition  parameters  (level  of  inspiration,  mAs,
V,  collimation)  and  reconstruction  (section  thickness,  ﬁl-
er)  settings  [83,84].  Overlapping  millimeter  sections  are
deal,  particularly  for  the  smallest  nodules  [85].  A  standard
econstruction  ﬁlter  is  recommended  [61].  Despite  these
recautions,  volume  measurements  can  be  subject  to  some
nter-examination  variability  which  is  estimated  to  be  13%
y  Goodman  [86].  Inter-observer  reproducibility  on  the  same
nvestigation  is,  however,  excellent.
hat type of CT acquisition?
nenhanced  scans  are  the  only  investigations  required  in  the
anagement  strategy  for  lung  nodules.  Positron  emission
omography  (PET)  has  a  marginal  role  in  characterization
nd  follow-up  but  is  essential  when  excision  surgery  is  con-
idered,  in  order  to  conﬁrm  that  no  extrapulmonary  lesions
re  present.  CT  acquisitions  should  combine  a  detailed
nvestigation  of  the  lung  volume  with  high  three-dimensional
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patial  resolution,  at  the  lowest  possible  radiation  dose.
n  follow-up  of  a  known  nodule,  the  acquisition  may  be
estricted  to  the  volume  of  interest  [87].  Collimation  should
deally  be  under  one  millimeter  and  the  reconstructions  per-
ormed  using  thin  overlapping  sections  [79].  Ground  glass
odules  can  only  be  correctly  analyzed  with  sections  of
nder  3  mm  [88]  and  the  Fleischner  Society  recommends
 mm  sections  [89].
In terms  of  acquisition  settings,  the  tube  voltage  is  gen-
rally  100  kV  although  this  should  be  adjusted  in  accordance
ith  the  patient’s  body  mass  index.  An  intensity  of  80  mAs
s  recommended  for  a  person  of  average  body  morphology
90], although  this  may  be  reduced  further  (low  dose  mode)
ecause  of  the  very  good  natural  contrast  between  lung  tis-
ue  and  nodules.  The  low  dose  mode  is  the  standard  for  all
f  the  major  screening  studies  in  which  repeated  CT  scans
re  performed.  There  is,  however,  no  precise  deﬁnition  of
 low  dose  chest  CT  and  in  practice  it  would  appear  rea-
onable  to  obtain  the  acquisition  at  between  25  and  50  mAs
91,92],  although  some  go  down  as  far  as  10  mAs  [93].  Iter-
tive  reconstructions  allow  the  dose  to  be  reduced,  at  the
ame  time  maintaining  reliable  volumetric  measurements
94], although  their  exact  inﬂuence  on  volumetry  is  not  yet
ufﬁciently  well  known.  In  bronchial  cancer  screening,  it
s  recommended  that  the  dose  length  product  should  not
xceed  150  mGy.cm  for  an  average  70  kg  adult  [61].  The
ean  effective  dose  per  scan  in  the  NLST  study  was  1.5  mSv
nd  in  the  NELSON  study  a  volume  dose  index  was  deﬁned
ccording  to  patient  weight:  0.8  mGy  if  <  50  kg,  1.6  mGy  if
0—80  kg  and  3.2  mGy  if  >  80  kg  [75].  Future  screening  stud-
es  will  probably  incorporate  the  risk  of  radiation-induced
alignancy  into  the  speciﬁc  mortality  rate  calculation  [95].
anagement principles
y  deﬁnition,  a  lung  nodule  (<  3  cm)  is  a  potential  T1  cancer,
hich  therefore  carries  a  high  likelihood  of  survival  after
esection.  All  lung  nodules  must  therefore  be  treated  in  a
tandardized  way,  with  the  aim  of  not  delaying  resection  of
 bronchial  cancer.  In  the  absence  of  formal  criteria  indi-
ating  a  benign  lesion,  the  radiologist  should  indicate  the
anagement  strategy  in  his/her  investigation  report.  This
ay  involve:
CT  scan  follow-up  if  the  nodule  is  equivocal  (and  the  spe-
ciﬁc  details  of  this  follow-up  should  also  be  stated);
an  invasive  approach  if  criteria  that  strongly  suggest
malignancy  are  present,  in  which  case  the  multidisci-
plinary  team  meeting  (MDT)  should  decide  on  the  most
appropriate  procedure.
The  strategy  proposed  here  is  for  a  single  nodule.  When
everal  nodules  are  present,  in  the  absence  of  a  clear  cause
uch  as  infection,  granulomatosis  or  metastatic  disease,  the
anagement  is  dictated  by  the  most  suspicious  nodule.
riteria for benign diseasehe  ﬁrst  step  is  to  examine  for  formal  criteria  of  benign
isease.  Benign  lung  parenchymal  lesions  are  relatively  few.
ome  of  these  can  be  identiﬁed  on  the  scan  using  well-known
riteria:
1087
Figure 5. Typical appearance of an intrapulmonary lymph node.
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• fatty  plaque  (−40  to  −120  HU)  within  the  nodule  suggest-
ing  a  hamartochondroma,  this  must  be  measured  carefully
with  a  low  standard  deviation  of  the  density  values;
• a completely  calciﬁed  nodule  or  one  containing  central
calciﬁcation,  suggestive  of  a  post-infectious  granuloma.
The  central  calciﬁcation  feature  should  be  conﬁrmed  on
two  orthogonal  reconstructions  (Fig.  4);
• a  polygonal  nodule  under  10  mm  in  size,  located  less
than  10  mm  from  the  pleura  or  connected  to  a  septum
and  beneath  the  carina,  suggestive  of  an  intrapulmonary
lymph  node  (Fig.  5).
These  criteria  are  very  speciﬁc  but  are,  however,  less
sensitive.  Only  50%  of  hamartochondromas,  for  example,
contain  a  visible  fatty  plaque  on  a  CT  scan  [96].  It  may
provide  reassurance  to  ensure  that  the  nodule  is  stable  with
a  repeat  CT  at  6  months,  for  example,  if  a  small  fatty  plaque
is  present  but  difﬁcult  to  measure.
Criteria for malignant disease
In  the  absence  of  criterion  for  benign  disease,  the  sec-
ond  step  involves  identifying  formal  criteria  for  malignancy
[7,97—100]:  a  solid  or  sub-solid  nodule  measuring  more  than
10  mm  in  diameter,  with  spiculated  or  lobulated  outlines,  an
air  bronchogram  or  pleural  retraction  (Fig.  6).  The  patient
i
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b
Figure 4. Lung granuloma with central calciﬁcation. Native axial sec
showing a solid tissue nodule in the culmen measuring 22 mm in diamet
containing a single, central, punctiform calciﬁcation. The coronal (c) and riangular nodule (arrow), 4 mm in diameter, adhering to a septum
nd located beneath the carina.
hould  be  referred  to  a  specialist  consultation  for  invasive
nvestigations  to  establish  its  histological  type.  Management
ptions  may  be  discussed  in  the  MDT.
In  most  cases,  however,  the  morphological  features  of
enign  and  malignant  disease  are  not  present  and  the
tions in the parenchymal window (a) and mediastinal window (b)
er, adhering to the scissure, with clearly demarcated outlines and
sagittal (d) reconstructions conﬁrm that the calciﬁcation is central.
1088  
Figure 6. Nodule, highly suspicious of malignancy. A nodule in the
right lung apex measuring 26 mm in diameter, of mixed density with
an internal bronchogram containing ﬁne peripheral spikes which,
following excision, was found to be an invasive adenocarcinoma
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Solid nodulesith a lepidic predominant component.
odule  is  still  indeterminate.  In  that  situation,  size  and
ensity  factors  need  to  be  considered,  often  adding  the
rogression  factor  with  CT  scan  monitoring.  Following  up
 nodule  over  time  has  the  advantage  of  being  non-invasive
ut  makes  the  management  more  complex  as  it  necessitates
olumetry  software  and  decision-making  algorithms.  Whilst
 nodule  that  is  solid  and  stable  over  2  years  is  considered
enign,  this  concept  is  not  valid  for  ground  glass  nodules
hich  can  have  a  long  CT  scan  latent  period  before  trans-
orming  into  a  more  aggressive  lesion.  The  question  of  how
ong  these  nodules  need  to  be  followed  up  for  has  not  yet
een  resolved.  Some  believe  that  this  should  be  for  at  least
 years,  or  even  longer.
ure ground glass nodules
 ground  glass  nodule  may  represent  one  of  several  different
esions  [101,102]:  local  infection,  local  inﬂammation  in  an
rganized  pneumonia,  spot  of  ﬁbrosis,  atypical  adenomatous
yperplasia  or  adenocarcinoma  in  situ.  If  the  nodule  is  under
 mm  in  size,  the  likelihood  of  malignancy  is  very  low  [103]
nd  no  monitoring  is  recommended  [89]  although  some  rec-
mmend  a  repeat  CT  at  one  year.  If  many  small  nodules  are
resent,  these  are  more  likely  to  represent  atypical  adeno-
atous  hyperplasia  [104]  and  should  then  be  followed  up  by
n  annual  scan  for  2  to  4  years  [89].  If  the  nodule  is  over
 mm  in  size,  a  scan  at  3  months,  possibly  after  antibiotic
herapy,  will  distinguish  between  a  transient  nodule  (infec-
ion,  inﬂammation)  and  a  persistent  nodule  adenocarcinoma
n  situ.  An  air  bronchogram  is  suggestive  of  adenocarcinoma
n  situ  [105].  However,  the  management  of  the  nodule  is
ictated  above  all  by  its  progression.  Lesions  which  have
ncreased  in  diameter  (≥  2  mm)  or  in  which  a  solid  compo-
ent  has  developed,  should  be  discussed  in  an  MDT  where
xcision  surgery  should  be  considered,  depending  on  the
linical  situation  [61,89].  Long-term  monitoring  should  be
roposed  for  lesions  which  are  stable  at  3  months,  through  a
inimum  of  one  annual  scan  for  3  years  [89],  as  75%  of  these
re  adenocarcinomas  in  situ  [102].  A  very  rapidly  growing
round  glass  nodule  should  suggest  infection,  inﬂammation
S
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r  metastasis  [106]. There  is  no  role  for  PET  in  monitoring
ure  ground  glass  nodules  [89].
art-solid nodules
 part-solid  nodule  is  more  suspicious  than  a  pure  ground
lass  nodule  and  needs  more  aggressive  management  if  it
ersists  [89,107].  This  usually  represents  minimally  invasive
denocarcinoma  or  lepidic  predominant  adenocarcinoma,
lthough  there  may  be  overlaps  with  the  other  lesions  from
he  adenocarcinoma  spectrum  (Fig.  3).  A  part-solid  nod-
le  can  also  be  benign,  infectious  or  inﬂammatory  [108].
 repeat  CT  at  3  months,  possibly  after  antibiotic  therapy,
s  therefore  recommended  for  all  of  these  cases  [61,89,90].
he  total  diameter  of  the  lesion  and  the  diameter  of  the
olid  central  component  should  be  measured  as  the  size
f  the  central  component  correlates  with  the  likelihood  of
alignancy  [29,35,109]  although  one  study  reported  differ-
nt  results  [100].  The  nodule  should  be  discussed  in  an  MDT
n  order  to  consider  surgical  excision  if  the  lesion  increases
n  diameter  (≥2mm)  and/or  if  the  solid  component  increases
61]. If  the  lesion  is  stable  at  3  months  and  has  a  solid  com-
onent  of  over  5  mm,  the  likelihood  of  invasive  cancer  is
till  signiﬁcant  and  it  should  also  be  discussed  in  an  MDT
89]. This  cut-off  of  5  mm  histologically  reﬂects  the  distinc-
ion  between  a  minimally  invasive  adenocarcinoma  of  very
ood  prognosis  and  an  invasive  adenocarcinoma,  which  car-
ies  a  signiﬁcantly  poorer  prognosis.  Annual  follow-up  for  3
o  5  years  is  recommended  for  nodules  which  are  stable  at
 months  and  have  a  solid  component  of  5  mm  or  less.
PET  CT  is  reported  to  be  useful  for  nodules  with  a  solid
omponent  of  over  10  mm  [110],  although  such  a  size  alone
s  sufﬁciently  suspicious  to  warrant  immediate  surgery.  As
 result,  in  reality,  the  PET  CT  is  more  part  of  the  staging
ssessment  than  a  diagnostic  tool  for  the  nodule.  It  should
lso  be  remembered  that  false  positive  PET  CT  results  are
ot  particularly  uncommon  (in  infection  or  inﬂammation).
ypereosinophilia  may  help  to  characterize  mixed  nodules
100].  This  is  a  very  highly  speciﬁc  ﬁnding  (97%)  but  unfor-
unately  less  sensitive  (38%).  This  strategy,  however,  has  not
et  been  demonstrated  to  be  sufﬁciently  useful.
Giving  antibiotics  with  a  repeat  scan  at  3  months  is  rela-
ively  empirical.  Between  37  and  70%  of  nodules  containing
round  glass  appearances  in  the  screening  studies  have  been
hown  to  be  transient  [100,108],  although  antibiotic  ther-
py  as  a test  to  abolish  these  has  not  been  shown  to  be
eneﬁcial.  The  only  study  on  this  subject  was  retrospective
nd  showed  no  difference  between  groups  which  were  and
hich  were  not  given  antibiotic  therapy  [111].  Expert  opin-
ons  are  split  between  those  who  recommend  it  [3,61,112]
nd  those  who  are  opposed  to  it  [69,89,113].  Other  ques-
ions  remain,  such  as  the  difﬁculty  of  distinguishing  a  pure
round  glass  nodule  from  a  sub-solid  nodule  for  lesions  under
 mm  in  size.  Some  adenocarcinomas  may  also  transiently
ecrease  slightly  in  size  because  of  ﬁbrosis  or  atelectasis
38,60,114],  although  these  changes  are  often  associated
ith  a  concomitant  increase  in  tumor  attenuation.olid  nodules  are  the  most  common,  although  only  2  to  7%
re  malignant  [5,115],  explaining  the  very  large  number
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of  false  positives  in  the  screening  studies.  It  is  essential,
therefore,  to  try  to  limit  the  number  of  non-contributory
investigations.  Volumetry  techniques  should  help  to  reduce
the  number  of  follow-up  scans  and  patient  radiation.
Three  situations  exist  depending  on  the  size  of  the  nod-
ule.  Nodules  over  10  mm  in  diameter  are  very  suspicious  of
malignancy  and  should  be  discussed  in  an  MDT  with  a  view
to  surgical  resection  [61].  Nodules  under  5  mm  in  size  are
very  rarely  malignant  and  require  annual  follow-up  only  if
they  are  over  3  mm  in  size  and  have  developed  in  a  patient
with  risk  factors  (age  >  40  years  old,  smoking  >  30  pack-years,
exposure  to  asbestos,  past  history  of  neoplasia)  [69].  Nod-
ules  between  5  and  10  mm  in  diameter  should  be  checked
at  3  months  with  volume  measurements  at  D0  and  D90  to
calculate  the  volume  doubling  time.  If  the  doubling  time  is
under  400  days,  which  generally  represents  an  increase  in
volume  of  over  25%,  the  nodule  is  deemed  to  be  very  likely
malignant  and  should  be  discussed  in  an  MDT  [61].  If  not,  a
follow-up  scan  at  1  year  is  recommended.  If  software  is  not
available  or  volumetry  cannot  be  performed,  as,  for  exam-
ple,  with  vascular  or  chest  wall  contact,  the  diameter  must
be  measured  carefully  by  displaying  the  two  investigations
simultaneously  and  zooming  onto  the  nodule  in  question.  An
increase  in  diameter  of  more  than  2  mm  is  deemed  to  be
positive.
Examination  for  enhancement  of  under  15  HU  after  injec-
tion  to  conﬁrm  that  a  lesion  is  benign  [116]  is  complex  in
practice,  involves  considerable  radiation  (4  successive  spi-
ral  acquisitions  1,  2,  3  and  4  minutes  after  injection)  and  is
only  really  reliable  for  nodules  over  8  mm  in  diameter.  This
method  should  no  longer,  therefore,  be  used  [87].  Similarly,
the  performance  of  PET  is  limited  for  lesions  under  a  cen-
timeter  in  size  [117].  The  advantage  of  volumetry  lies  in  the
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Figure 7. Tabulated summary of the management of lung nodules. CT:
a view to surgery; RF: risk factors; VDT: volume doubling time; a: surg
considered on an individual case basis; b: criteria for benign disease: (i) c
containing a fatty plaque (−40 to −120 HU); (iii) triangular or polygonal n
the carina, less than 10 mm from a pleural lining or ﬁssure; c: RF: (i) 
(iv) past history of neoplasia; d: if volumetry cannot be performed, an
malignancy and discussed in the MDT.
Table produced from the expert consensus recommendations [61,69,89,91089
act  that  it  is  non-invasive,  as  it  does  not  require  injection,
nd  it  involves  only  low  doses  of  radiation  as  the  acquisition
olume  can  be  reduced  to  the  region  of  interest.
ummary table
he  sheer  variety  of  cases  occurring  make  an  analytical
pproach  difﬁcult,  and  a  decision-support  guide  summa-
izing  the  most  appropriate  strategy  for  each  situation  is
herefore  necessary.  Within  the  summary  table,  we  prof-
er  a  tabulated  summary  which  is  sufﬁciently  exhaustive
o  cover  all  of  the  cases,  but  which  is  also  simple  to  use
Fig.  7).  Some  speciﬁc  clinical  presentations,  however,  may
all  outside  of  this  general  approach  and  require  speciﬁc
iscussion  in  an  MDT.  This  particularly  applies  to  elderly  or
‘borderline’’  surgical  patients.  Management  may  also  dif-
er  slightly  depending  on  whether  or  not  the  ﬁnding  comes
rom  screening.  It  is  reassuring,  for  example,  to  know  that
 patient  with  a  4  mm  ground  glass  lesion  who  is  a  smoker
ill  anyway  beneﬁt  from  follow-up  as  part  of  the  screening.
his  table  does  not  provide  information  about  the  invasive
trategy  to  be  used  (biopsy  or  surgery,  and  type  of  surgery)
s  this  decision  should  be  taken  on  a  joint  basis  by  all  of
hose  present  in  the  MDT.
he MDT. When to perform a biopsy?
he  Cancer  plan  launched  in  2003  made  MDT’s  obligatory
or  all  patients  suffering  from  cancer,  which  might  be  held
efore  starting  initial  treatment  or  before  any  signiﬁcant
hange  in  treatment  [118].  The  MDT  is  based  on  good
ractice  recommendations  in  order  to  offer  standardized
5-10 mm > 10 mm
 CT  at  3 months  wi th nodu le
umet ry
d
 at D0 and  D90:
T   400  da ys:  CT  at  1 year
T < 400 days: MDT
table  at 3 months:  1 C T/year f or 3-5  years
MDT
3 mont hs (± after  anti biotic  therapy):
ponent > 5 m m: MD T
Follow-up CT at 3 months (± after antibiotic therapy):
rowth    2mm or  de velopment  of  a solid  compon ent:  MD T
a
 compon ent    5 mm:  1 CT/year for  3-5 years
 computed tomography; MDT: Multidisciplinary Team Meeting with
ery not performed routinely for pure ground glass nodules, to be
omplete or central calciﬁcation (in two perpendicular planes); (ii)
odule with smooth edges, less than 10 mm in size, located beneath
age > 40 years old; (ii) smoking > 30 PA; (iii) exposure to asbestos;
 increase in diameter over 2 mm should be considered suspect of
0].
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anagement  to  each  patient.  A  recent  study  has  shown
hat  MDTs  have  a  signiﬁcant  impact  on  patient  management,
articularly  by  increasing  access  to  treatments  such  as  radio-
herapy  and  chemotherapy,  although  this  does  not  appear  to
ffect  survival  [119].  As  in  other  specialties,  the  radiologist
lays  an  essential  role  in  the  MDT  in  thoracic  oncology  and
s  involved  in  all  phases  of  management.
Although  there  are  no  clear  recommendations  in  this
eld,  we  feel  that  any  biopsy  of  a  nodular  lesion  should  ide-
lly  be  discussed  in  an  MDT  so  that  the  decision  on  the  biopsy
an  be  made  in  view  of  the  planned  treatment  strategies.
iopsy  under  CT  guidance  is  a  relatively  simple  technique,
lthough  it  is  not  without  morbidity.  The  correct  indica-
ion  for  biopsy  is  one  in  which  the  results  will  inﬂuence
ubsequent  management  and  beneﬁt  the  patient.  An  inop-
rable  nodule,  because  of  metastatic  spread,  or  a  patient
ho  is  inoperable  for  clinical  safety  reasons  are  generally
orrect  indications  for  a  biopsy.  Conversely,  if  the  CT  scan
s  highly  suggestive  of  a  primary  lung  lesion  with  no  sig-
iﬁcant  lymph  node  or  distant  localization,  a  preoperative
iopsy  may  be  questionable.  Some  groups  organize  ﬁrst-line
urgical  excision  with  extemporaneous  histological  exami-
ation.  Others  perform  a  biopsy  whenever  possible,  which
ccasionally  reveals  alternative  diagnoses  and  may  help
he  surgeon  to  plan  video-assisted  lobectomy.  If  a  nodule
s  associated  with  hypermetabolic  mediastinal  adenopathy,
ndobronchial  ultrasound  or  mediastinoscopy  are  proba-
ly  more  appropriate,  as  this  will  provide  tumor  histology
ogether  with  ‘‘N  staging’’  and  could  be  followed  by  thora-
otomy  for  lung  resection.  It  is  important  also  to  remember
hat  the  absence  of  malignant  cells  in  a  biopsy  never  guar-
ntees  that  the  mass  is  benign.  The  distinction  between  a
rimary  bronchial  carcinoma  and  a  single  metastasis  remains
 correct  indication  for  biopsy.
When  biopsy  is  indicated,  a  few  simple  rules  should  be
ollowed.  There  is  no  advantage  in  carrying  out  a  biopsy  on
 ground  glass  lesion,  which  usually  represents  a  lepidic  com-
onent.  The  solid  portion  of  a  mixed  nodule  should  therefore
e  targeted.  For  large  tissue  nodules,  it  is  essential  to  tar-
et  the  contrast-enhanced  or  hypermetabolic  PET  areas  if
revious  investigations  are  available.  The  aim  of  this  is  to
void  necrotic  regions  which  cannot  be  interpreted  histolog-
cally.  The  purpose  of  a  nodule  biopsy  in  inoperable  patients
s  to  obtain  sufﬁcient  material  for  molecular  typing  of  a  pos-
ible  adenocarcinoma  and  particularly  to  test  for  the  EGFR
ene  mutation.  An  alternative  to  biopsy  is  ﬁne-needle  aspi-
ation,  which  usually  allows  EGFR  subtyping  to  be  performed
fter  including  the  centrifugation  deposit  obtained  in  paraf-
n  [120].  Some  people  recommend  repeating  the  biopsies  in
atients  who  do  not  respond  to  ﬁrst-line  treatment,  because
f  the  histological  molecular  heterogeneity  of  the  tumors.
hich treatment for which nodule?
he  different  treatment  options  (surgery,  radiotherapy,
hemotherapy,  radiofrequency  ablation,  etc.)  are  decided
ointly  in  an  MDT.  The  clinical  situations  vary  greatly  and
ake  it  difﬁcult  to  construct  decision-support  algorithms.
lso,  there  are  not  very  many  recommendations  that  are
ased  on  high  levels  of  evidence.  Each  indication  must  there-
ore  be  considered  on  a  case-by-case  basis,  depending  onM.  Lederlin  et  al.
he  appearance  of  the  lesions,  the  patient’s  age  and  gen-
ral  health,  and  the  techniques  and  skills  available  in  each
entre.
In  proven  malignancy,  the  reference  treatment  is  still
obectomy  and  mediastinal  lymph  node  dissection.  Lung
paring  surgery  is  recommended  for  ground  glass  nodules
89], ideally  under  video-assisted  thoracoscopy  which  has  a
ower  morbidity  than  conventional  thoracotomy  [121—123].
his  may  involve  atypical  (‘‘wedge’’)  resection,  segmentec-
omy  or  sub-segmental  resection.  Lymph  node  curettage  is
ecommended,  particularly  if  the  nodule  has  a  solid  invasive
omponent.  The  surgeon  must  be  able  to  identify  the  nodule
n  palpation,  which  may  be  more  or  less  difﬁcult  depending
n  its  size,  density  and  whether  it  is  central  or  peripheral.
rior  identiﬁcation  with  a  harpoon,  coil  or  methylene  blue
an  be  carried  out,  particularly  for  the  smallest  and  most
entral  lesions  [124—126]. These  identiﬁcations,  however,
ay  be  difﬁcult  (there  is  a  risk  of  the  coil  or  harpoon  mov-
ng  and  surgery  needs  to  be  scheduled  immediately  after  the
can).  Above  all,  surgeons  want  a  detailed  analysis  of  the
egmental  location  of  the  nodule.  In  the  case  of  multiple
odules,  the  choice  of  surgical  procedure  may  be  complex.
ultiple  ground  glass  nodules  are  more  likely  to  be  syn-
hronous  primary  tumors  than  metastatic  nodules  [28,127].
inally,  the  role  of  radiofrequency  ablation  has  not  yet  been
ufﬁciently  examined  but  remains  restricted,  as  does  stereo-
actic  radiotherapy,  to  inoperable  patients.
onclusion
 considerable  amount  of  new  knowledge  has  emerged  in
ecent  years,  which  has  signiﬁcantly  changed  the  manage-
ent  of  the  lung  nodule.  Deﬁning  the  non-invasive  nature
f  a  nodule  is  still  almost  exclusively  the  role  of  CT.  This
ow  also  involves  measurements  of  diameter,  volume  and
ensity.  Densitometric  analysis  appears  to  correlate  particu-
arly  well  with  the  disease  spectrum  of  adenocarcinomas.  In
iew  of  the  high  detection  capacity  of  CT,  the  prevalence  of
ung  nodules  found  upon  CT  scanning  is  high  and  continues  to
ncrease  with  the  lung  cancer  screening,  which  is  currently
eveloping.  It  is  important,  therefore,  that  radiologists  are
amiliar  with  these  new  concepts  and  can  recommend  opti-
al  management.
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